VolitionRX Signs Licencing Agreements With Werfen and Hologic
I'm PortAI, I can summarize articles.
VolitionRx Limited has signed two significant agreements in 2025 as part of its human licensing strategy. The first is with Werfen for Antiphospholipid Syndrome (APS), and the second is a Co-Marketing and Services Agreement with Hologic. Additionally, VolitionRx signed an agreement with a leading pharmaceutical company to use its Nu.Q® Discover biomarkers in a Phase 1/2b clinical study.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments